PKO Investment Management Joint Stock Co Sells 500 Shares of Eli Lilly and Company $LLY

PKO Investment Management Joint Stock Co reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 3.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,926 shares of the company’s stock after selling 500 shares during the period. Eli Lilly and Company comprises 0.9% of PKO Investment Management Joint Stock Co’s portfolio, making the stock its 23rd largest holding. PKO Investment Management Joint Stock Co’s holdings in Eli Lilly and Company were worth $10,626,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of LLY. Sumitomo Mitsui Financial Group Inc. bought a new position in Eli Lilly and Company in the 2nd quarter worth $27,000. Evolution Wealth Management Inc. purchased a new stake in Eli Lilly and Company in the second quarter worth about $29,000. Steph & Co. raised its stake in shares of Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after buying an additional 29 shares during the period. Financial Gravity Companies Inc. purchased a new position in shares of Eli Lilly and Company during the 2nd quarter valued at about $31,000. Finally, Bare Financial Services Inc grew its stake in shares of Eli Lilly and Company by 263.6% during the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 29 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s announced acquisition of Ventyx Biosciences offered a strategic complement to its weight‑loss franchise by targeting inflammation (data showed benefit when combined with GLP‑1 therapy); the deal helped calm investor concern after the Novo news and supported a rally. Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns
• Positive Sentiment: Lilly and NVIDIA will fund a $1B AI co‑innovation lab over five years to speed drug discovery and manufacturing—this could lower R&D costs and shorten time‑to‑market for new drugs, a multi‑year positive for pipeline value. Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab
• Positive Sentiment: Commercial demand traction: Humana’s CenterWell Pharmacy launching an employer program that uses Lilly’s GLP‑1 drugs underscores ongoing demand and distribution pathways for Lilly’s marketed products. Humana’s CenterWell Pharmacy Launches Employer Venture Using Lilly’s GLP-1 Drugs
• Neutral Sentiment: Company guidance and seasonality: Analysts expect double‑digit Q4 growth and Lilly has strong FY 2025/26 earnings expectations—these set a positive baseline but already appear priced into the stock. What to Expect From Eli Lilly’s Q4 2025 Earnings Report
• Neutral Sentiment: Lilly says it is confident about supply readiness for its oral weight‑loss candidate ahead of an anticipated U.S. approval—reduces one operational risk but doesn’t remove competitive or regulatory uncertainty. Lilly says it’s confident in weight-loss pill supply ahead of U.S. approval
• Negative Sentiment: Competitive pressure: Novo Nordisk’s immediate nationwide rollout of the Wegovy oral pill surprised some investors and triggered a pullback in LLY shares as markets priced higher competition in the oral GLP‑1 market. Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $1,075.90 on Wednesday. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The company has a market cap of $1.02 trillion, a P/E ratio of 52.64, a P/E/G ratio of 0.78 and a beta of 0.35. The firm’s fifty day moving average is $1,044.24 and its two-hundred day moving average is $865.79. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the prior year, the firm earned $1.18 EPS. The business’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.6%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is 33.86%.

Analysts Set New Price Targets

LLY has been the topic of a number of recent analyst reports. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a research note on Wednesday, November 19th. HSBC restated a “hold” rating and set a $1,070.00 price objective on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Bank of America dropped their target price on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a report on Monday, December 15th. CICC Research increased their price target on Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a research note on Thursday, November 13th. Finally, Leerink Partners set a $1,234.00 price objective on Eli Lilly and Company in a research report on Monday, January 5th. Five analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $1,169.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.